Hiteck grants Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ:NBP), exclusive worldwide rights, excluding Greater China, to develop and commercialize HT006.2.2
Hiteck retains all rights in Greater China, where a Phase 1b study in severe neurotrophic keratitis showed 50% complete corneal healing in the highest dose cohort after an 8-week course
HT006.2.2 is designed to offer a more convenient treatment option for patients with neurotrophic keratitis, building on Hiteck's longstanding expertise in nerve growth factor (NGF) therapeutics
WUHAN, China, Oct. 13, 2026 /PRNewswire/ -- Wuhan Hiteck Biological Pharma Co., Ltd. ("Hiteck") (SZSE: 300683) today announced that it has entered into an exclusive license agreement (the "License Agreement") with Visara, Inc. ("Visara"), a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, for HT006.2.2, an investigational next-generation modified recombinant human nerve growth factor (rhNGF) eye drop being developed for the treatment of neurotrophic keratitis (NK). Visara plans to develop HT006.2.2 as VIS-102.
Under the terms of the License Agreement, Visara will receive exclusive rights to develop and commercialize HT006.2.2 worldwide excluding Greater China, and Hiteck retains all rights in Greater China. Hiteck will receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments, as well as tiered royalties on net sales. A joint steering committee (JSC) will be responsible for the oversight and coordination of research and development activities under the License Agreement, technology transfer, management of the global development plan and expansion studies, information exchange, and such other functions as the parties may agree in writing.